Fentanyl/Hydromorphone
ApprovedSmall molecule
Fentanyl/Hydromorphone is one of 14 small molecule programs targeting Cleft Palate. It is currently in Approved.
1
Indications
3
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Cleft Palate
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Chirocaine
PPurdue Pharma LP
Phase 3
Methadone Hydrochloride
NNational Institute of Allergy and Infectious Diseases (NIAID)
Approved
TISSEEL
UUniversity Hospital, Ghent
Approved
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Marcaine
IInnocoll
Phase 2
Paracetamol
GSKPhase 2
Fentanyl/Hydromorphone
DDuke University
Approved
Unasyn
SStanford University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tonsillectomy2 trials
Pediatric Pain Optimization After Tonsillectomy
Completed·—·Phase 2·NCT05244226·66 enrolled
Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia
Recruiting·—·Phase 4·NCT06576830·440 enrolled
Cleft Palate1 trial
Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
Recruiting·—·Phase 4·NCT06962306·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fentanyl/Hydromorphone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDuke University